502 related articles for article (PubMed ID: 24231356)
1. Inhibition of mitochondrial fragmentation diminishes Huntington's disease-associated neurodegeneration.
Guo X; Disatnik MH; Monbureau M; Shamloo M; Mochly-Rosen D; Qi X
J Clin Invest; 2013 Dec; 123(12):5371-88. PubMed ID: 24231356
[TBL] [Abstract][Full Text] [Related]
2. S-nitrosylation of dynamin-related protein 1 mediates mutant huntingtin-induced mitochondrial fragmentation and neuronal injury in Huntington's disease.
Haun F; Nakamura T; Shiu AD; Cho DH; Tsunemi T; Holland EA; La Spada AR; Lipton SA
Antioxid Redox Signal; 2013 Oct; 19(11):1173-84. PubMed ID: 23641925
[TBL] [Abstract][Full Text] [Related]
3. A novel Drp1 inhibitor diminishes aberrant mitochondrial fission and neurotoxicity.
Qi X; Qvit N; Su YC; Mochly-Rosen D
J Cell Sci; 2013 Feb; 126(Pt 3):789-802. PubMed ID: 23239023
[TBL] [Abstract][Full Text] [Related]
4. Drp1 phosphorylation by MAPK1 causes mitochondrial dysfunction in cell culture model of Huntington's disease.
Roe AJ; Qi X
Biochem Biophys Res Commun; 2018 Feb; 496(2):706-711. PubMed ID: 29397067
[TBL] [Abstract][Full Text] [Related]
5. Increased mitochondrial fission and neuronal dysfunction in Huntington's disease: implications for molecular inhibitors of excessive mitochondrial fission.
Reddy PH
Drug Discov Today; 2014 Jul; 19(7):951-5. PubMed ID: 24681059
[TBL] [Abstract][Full Text] [Related]
6. Drp1/Fis1-mediated mitochondrial fragmentation leads to lysosomal dysfunction in cardiac models of Huntington's disease.
Joshi AU; Ebert AE; Haileselassie B; Mochly-Rosen D
J Mol Cell Cardiol; 2019 Feb; 127():125-133. PubMed ID: 30550751
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of excessive mitochondrial fission reduced aberrant autophagy and neuronal damage caused by LRRK2 G2019S mutation.
Su YC; Qi X
Hum Mol Genet; 2013 Nov; 22(22):4545-61. PubMed ID: 23813973
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of Drp1 hyperactivation reduces neuropathology and behavioral deficits in zQ175 knock-in mouse model of Huntington's disease.
Zhao Y; Sun X; Qi X
Biochem Biophys Res Commun; 2018 Dec; 507(1-4):319-323. PubMed ID: 30449600
[TBL] [Abstract][Full Text] [Related]
9. Mutant huntingtin's interaction with mitochondrial protein Drp1 impairs mitochondrial biogenesis and causes defective axonal transport and synaptic degeneration in Huntington's disease.
Shirendeb UP; Calkins MJ; Manczak M; Anekonda V; Dufour B; McBride JL; Mao P; Reddy PH
Hum Mol Genet; 2012 Jan; 21(2):406-20. PubMed ID: 21997870
[TBL] [Abstract][Full Text] [Related]
10. Hope for Huntington's disease? A novel approach for disease modification.
Tunc S; Capetian P; Münchau A
Mov Disord; 2014 Aug; 29(9):1117. PubMed ID: 24909788
[No Abstract] [Full Text] [Related]
11. VCP recruitment to mitochondria causes mitophagy impairment and neurodegeneration in models of Huntington's disease.
Guo X; Sun X; Hu D; Wang YJ; Fujioka H; Vyas R; Chakrapani S; Joshi AU; Luo Y; Mochly-Rosen D; Qi X
Nat Commun; 2016 Aug; 7():12646. PubMed ID: 27561680
[TBL] [Abstract][Full Text] [Related]
12. Mutant huntingtin binds the mitochondrial fission GTPase dynamin-related protein-1 and increases its enzymatic activity.
Song W; Chen J; Petrilli A; Liot G; Klinglmayr E; Zhou Y; Poquiz P; Tjong J; Pouladi MA; Hayden MR; Masliah E; Ellisman M; Rouiller I; Schwarzenbacher R; Bossy B; Perkins G; Bossy-Wetzel E
Nat Med; 2011 Mar; 17(3):377-82. PubMed ID: 21336284
[TBL] [Abstract][Full Text] [Related]
13. The Putative Drp1 Inhibitor mdivi-1 Is a Reversible Mitochondrial Complex I Inhibitor that Modulates Reactive Oxygen Species.
Bordt EA; Clerc P; Roelofs BA; Saladino AJ; Tretter L; Adam-Vizi V; Cherok E; Khalil A; Yadava N; Ge SX; Francis TC; Kennedy NW; Picton LK; Kumar T; Uppuluri S; Miller AM; Itoh K; Karbowski M; Sesaki H; Hill RB; Polster BM
Dev Cell; 2017 Mar; 40(6):583-594.e6. PubMed ID: 28350990
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of Drp1 mitochondrial translocation provides neural protection in dopaminergic system in a Parkinson's disease model induced by MPTP.
Filichia E; Hoffer B; Qi X; Luo Y
Sci Rep; 2016 Sep; 6():32656. PubMed ID: 27619562
[TBL] [Abstract][Full Text] [Related]
15. Mitochondrial fission and cristae disruption increase the response of cell models of Huntington's disease to apoptotic stimuli.
Costa V; Giacomello M; Hudec R; Lopreiato R; Ermak G; Lim D; Malorni W; Davies KJ; Carafoli E; Scorrano L
EMBO Mol Med; 2010 Dec; 2(12):490-503. PubMed ID: 21069748
[TBL] [Abstract][Full Text] [Related]
16. Small-molecule suppression of calpastatin degradation reduces neuropathology in models of Huntington's disease.
Hu D; Sun X; Magpusao A; Fedorov Y; Thompson M; Wang B; Lundberg K; Adams DJ; Qi X
Nat Commun; 2021 Sep; 12(1):5305. PubMed ID: 34489447
[TBL] [Abstract][Full Text] [Related]
17. ATAD3A oligomerization causes neurodegeneration by coupling mitochondrial fragmentation and bioenergetics defects.
Zhao Y; Sun X; Hu D; Prosdocimo DA; Hoppel C; Jain MK; Ramachandran R; Qi X
Nat Commun; 2019 Mar; 10(1):1371. PubMed ID: 30914652
[TBL] [Abstract][Full Text] [Related]
18. Declines in Drp1 and parkin expression underlie DNA damage-induced changes in mitochondrial length and neuronal death.
Wang DB; Garden GA; Kinoshita C; Wyles C; Babazadeh N; Sopher B; Kinoshita Y; Morrison RS
J Neurosci; 2013 Jan; 33(4):1357-65. PubMed ID: 23345212
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of Drp1/Fis1 interaction slows progression of amyotrophic lateral sclerosis.
Joshi AU; Saw NL; Vogel H; Cunnigham AD; Shamloo M; Mochly-Rosen D
EMBO Mol Med; 2018 Mar; 10(3):. PubMed ID: 29335339
[TBL] [Abstract][Full Text] [Related]
20. Involvement of CRMP2 in Regulation of Mitochondrial Morphology and Motility in Huntington's Disease.
Brustovetsky T; Khanna R; Brustovetsky N
Cells; 2021 Nov; 10(11):. PubMed ID: 34831395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
